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1. Introduction
Ataxia Telangiectasia (A-T) is an autosomal recessive hereditary progressive neurodegener‐
ative and multisystem disease characterized by cerebellar ataxia, telangiectasia, recurrent si‐
nopulmonary infections, variable immunologic defects among which a significantly higher
incidence of leukaemia and lymphoma and type 2 diabete. This disorder has been clearly
linked to the loss of expression of the serine/threonine kinase ATM (Ataxia Telangiectasia
Mutated), a central player of the DNA Damage Response (DDR). Several clinical features of
A-T patients, as well as the pleiotropic phenotypes observed in Atm deficient mice, can be
associated to a defective DDR. Moreover, ATM deficient cellular models display radiosensi‐
tivity and failure to activate cell cycle checkpoints in response to DNA damaging agents.
Emerging evidences indicate that ATM kinase may be involved in several additional signal‐
ling pathways, among which the signalling cascades triggered by oxidative stress, hypoxia,
autophagy, metabolic changes, growth factors and death receptors, suggesting that the en‐
dangerment of these functions in the absence of ATM activity may importantly contribute to
the development of A-T pathology.
The aim of this chapter is to provide a schematic, although exhaustive, description of the
signalling cascades that may modulate and may be modulated by ATM kinase activity. Data
obtained from different model systems, including in vitro and in vivo studies, human and
mouse models will be integrated. The chapter will be subdivided in paragraphs to improve
the readability and to emphasize different aspects of the genetic, molecular and functional
features of this pathology. The structure of the protein as well as its primary function in the
DDR will be discussed. However, particular emphasis will be given to the enrolment of
ATM to other signalling pathways and to the molecular mechanisms that ensure ATM kin‐
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ase activity regulation. Finally, we will deeply discuss the functional links between ATM
kinase and cancer, immune system defects and neurodegeneration.
2. Ataxia telangiectasia pathology
Ataxia-telangiectasia (A-T) [1], is a multisystem neurodegenerative syndrome that occurs
early in childhood. A-T is an autosomal recessive disease with an estimated frequency in the
range of one per 40000 to one per 300 000 births. At birth, infants generally appear normal
and begin walking at a normal age (approximately age 1 year); however, by age 2–3 ataxia
(loss of muscle co-ordination) becomes visible and generally by age 10 patients are confined
to a wheelchair (for a recent review [2]). Clinically, A-T presents with uncoordinated or atax‐
ic movements that are often associated with ocular telangiectasia (dilated blood vessels of
the eye). Ataxia generally precedes telangiectasia, which is described as the chronic dilation
of a group of capillaries causing elevated, dark red blotches on the skin or eyes. The promi‐
nent neurological sign of A-T is an inexorable loss of cerebellar function, and progressive
dysarthria (speech defects) and choreoathetosis (abnormal body movements). Studies have
shown a gradual decrease in granular and Purkinje cells, which are large branching cells of
the nervous system and are located in the cerebellum. Characteristic eye movement abnor‐
malities also feature strongly in A-T, and these might be related to cerebellar dysfunction.
Although, the hallmark of clinical presentation is a debilitating progressive neurodegenera‐
tion, other characteristics are associated with A-T, such as extreme radiosensitivity, immu‐
nodeficiency (frequently manifested as decreased or absent IgA, IgE and IgG2), cancer
predisposition (particularly lymphoma and leukaemia), insulin-resistant diabetes and pre‐
mature aging.
Clinical diagnosis of A-T is relatively easy once the characteristic neurodegeneration and
ocular  telangiectasia  have  developed.  In  these  cases  the  diagnosis  can  usually  be  con‐
firmed by finding an elevated serum α-fetoprotein  level,  although so  far  it  is  not  clear
why α-fetoprotein remains high in A-T patients since there is no obvious liver damage. In
young children where ataxia and/or telengiectasia did not occur yet, the diagnosis is still
challenging. A-T pathology has been clearly linked to the loss of function of the product
of the ATM gene. Most patients are compound heterozygotes with different mutations in
the  two  ATM  alleles.  The  identification  of  the  ATM  gene  has  facilitated  diagnosis,  al‐
though the  large  dimensions  of  the  gene and the  lack of  mutational  hot  spots,  prevent
mutational analysis for clinical screening. Additional confirmatory laboratory test results
include absence of the ATM protein on immunoblots, lack of ATM protein kinase activi‐
ty, increased frequency of chromosomal breaks after exposure to γ-radiation, radioresist‐
ant  DNA  synthesis  and  decreased  colony  survival  after  γ-radiation.  None  of  these
methods is 100% specific or 100% sensitive, and clinical correlation is essential.  The two
most common causes of death are chronic lung disease (about one-third of cases) and can‐
cer (about one-third of cases) (reviewed in [2]).
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3. Genetic and molecular bases of A-T: From ATM gene to ATM protein
Ataxia–telangiectasia (A-T) is a rare autosomal recessive disorder caused by deficiency of
the Ataxia–Telangiectasia Mutated (ATM) protein kinase. A-T patients generally lack func‐
tional ATM protein due to missense or nonsense mutations in the ATM gene, which has
been identified by positional cloning strategy in 1995 [3].
These mutations occur throughout the entire coding sequence of the gene and overall lead
to the production of truncated or unstable ATM variants [4]. The human ATM gene is locat‐
ed at 11q22-23 and covers 160 kb of genomic DNA; the gene product, ATM protein, is pro‐
duced from a 13 kb transcript that codes for a 350 kDa protein.
ATM protein belongs to the phosphatidylinositol 3 kinase-like kinase (PIKK) family of Ser/
Thr-protein kinases, which includes ATR (ataxia–telangiectasia and RAD3-related), DNA-
PKcs (DNA-dependent protein kinase catalytic sub-unit) and mTOR (mammalian target of
rapamycin), and many others. The proteins that are members of this family show a con‐
served domain organization in their C-terminal portion, which includes the presence of a
kinase domain, flanked by a FAT domain (conserved sequence in FRAP, ATM and TRAPP
proteins), that precedes the catalytic domain, and a FATC domain (FAT-C-terminal) that is
located at the very C-terminal of the protein. Interestingly the FAT and the FATC domain
have been proposed to play a role in the conformational maintenance of the catalytic do‐
main and therefore in the control of the functionality of these kinases [5]. This model is also
supported by the identification in these domains of several post-translational modifications
that play a role in the modulation of ATM activity. Among these, S1981 in the FAT domain,
a major autophosphorylation site that modulates the assembly of the inactive dimeric con‐
formation [6], and C2991 in the FATC, whose acetylation contributes to the modulation of
S1981 phosphorylation and to ATM kinase activation [7].
The N terminus of ATM is composed of HEAT (Huntingtin, Elongation factor 1A, protein
phosphatase 2A A-subunit, TOR) repeats [8]. Moreover, several motifs that allow ATM in‐
teraction with other proteins have been mapped in the N-terminal region of ATM. Among
these, sequences for the interaction with NBS1, c-Abl, p53, which play an essential role in
the regulation and in the execution of ATM function, as well as with chromatin. The protein
is heavily subjected to several post-translational modifications, among which phosphoryla‐
tions and acetylation, that overall play a role in the modulation of ATM kinase activity as
described in the next paragraph (for recent reviews on ATM [9] [10]).
4. ATM function: The DNA damage response
ATM function in the DNA damage response has been deeply investigated by several
groups. Several excellent reviews in this topic are currently available [9, 11-13]. For this rea‐
son this paragraph will only briefly summarize the state of the art on this issue.
ATM has been first identified as an essential component of the DNA damage response, a
complex of signalling cascades that ensures the maintenance of genomic stability. The oc‐
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currence of a DNA damage triggers cell cycle arrest and the initiation of the repair proc‐
ess.  Alternatively,  the  cell  that  contains  the  damaged  DNA  may  undergo  apoptosis  or
senescence. The molecular mechanisms that allow the choice among these responses have
not been clearly elucidated yet, although the common idea is that apoptosis or senescence
are  initiated  in  case  the  damage  in  not  repairable.  Genetic  defects  that  perturb  these
mechanisms almost invariably cause severe syndromes that are characterized by the de‐
generation of specific  tissues (especially the nervous and immune system),  sensitivity to
specific  DNA-damaging agents  and predisposition to  cancer  (reviewed in  [11],  see  next
paragraph on “DNA damage response and other genomic instability syndromes”). Differ‐
ent types of DNA damage may trigger different types of DNA repair responses (for a re‐
cent review see [13]).
In particular, ATM is major player of the cellular response to Double Strand Breaks which
represent the most toxic type of DNA lesion, elicited mainly by ionizing radiation (IR or γ-
radiation) and other genotoxic stresses. DSBs occur also during physiological processes such
as meiotic recombination and the assembly of the T-cell receptor and immunoglobulin genes
via V(D)J recombination, in T cells and B cells, respectively. The central role of ATM in the
DDR to DSBs has been strongly suggested by some observations derived from A-T patients
or Atm KO mice as well as from Atm deficient cells. Indeed A-T cells are highly sensitive to
IR, and are characterized by failure of checkpoint induction in response to IR. As already
pointed out, ATM deficiency leads both in human and mice to immune system defects (see
also next paragraph on “Functional links between ATM kinase and the immune system de‐
fects”) as well as to genomic instability and to higher incidence of cancer development (see
also next paragraph on “Functional links between ATM kinase and cancer”).
Within minutes after the induction of DSBs, most ATM molecules become vigorously ac‐
tive and participate to checkpoints activation, as well as to DNA repair and to the induc‐
tion of  senescence or apoptosis  [14].  Overall,  the signalling cascades that  allow ATM to
participate and modulate all these responses have been only partially elucidated and rely
on  the  ability  of  ATM  to  trigger  the  phosphorylation  of  a  large  number  of  substrates,
among which several kinases, that amplify the signal, and transcription factors, DNA re‐
pair components and other that execute the different responses (see also next paragraph
on “Identification of ATM substrates: proteomic studies”). The activation process includes
ATM recruitment to the DSBs, which is mediated by the MRN complex and by the dam‐
aged DNA (see next paragraph on “Molecular mechanisms that ensure the modulation of
ATM kinase activity”). Activation of this pathway includes a plethora of phosphorylation
and ubiquitination events triggered by ATM kinase, among which the activation of c-Abl
kinase which in turn modulates the activity of Rad51 and Rad52 proteins and the phos‐
phorylation  of  histone  H2AX  which  marks  the  DSBs.  Therefore  activated  ATM  partici‐
pates directly to the repair of the DNA lesion. In particular, ATM modulates Homologous
Recombination (HR) and contributes to repair also through its interplay with other PI3K-
like kinases such as ATR and DNA-PK.
Activated ATM is also released from the damaged DNA and may therefore trigger the cell
cycle checkpoints activation. ATM may modulate cell cycle arrest as well as the apoptotic or
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senescence induction. For these responses, among the others, a crucial effector of ATM sig‐
nalling is p53 transcription factor. ATM may modulate p53 functionality by directly phos‐
phorylating p53 on S15 (promoting p53 transcriptional activity) as well as via the activation
of Chk2 kinase, which in turn triggers p53 phosphorylation on S20 (impairing p53 interac‐
tion with Hdm2 ubiquitin ligase, therefore promoting its stabilization). Moreover ATM may
direcly phosphorylate and modulate Hdm2 and may also modulate HIPK2 and therefore
p53 phosphorylation on S46, which enhances p53 apoptotic activity. To summarize, the in‐
terplay between ATM and p53 is a good example of the complexity of the signalling cas‐
cades that modulate the balance and the integration of the different checkpoints with the
apoptotic response.
An exhaustive picture of the signalling cascades through which ATM modulates cell cycle,
cell death and DNA repair is beyond the scope of this chapter and it is available in these
suggested reviews [9, 11-13].
4.1. DNA damage response and other genomic instability syndromes
A-T belongs to a group of human diseases that are collectively known as “genomic instabili‐
ty syndromes”, each of which results from a defective response to a specific DNA lesion
[11]. Genetic defects that affect specific DNA damage response pathways lead to syndromes
that combine various degrees of tissue degeneration, growth and developmental retarda‐
tion, premature signs of ageing, chromosomal instability, sensitivity to the corresponding
DNA-damaging agents and cancer predisposition. The prominent genomic instability syn‐
dromes – Xeroderma pigmentosum (XP), Cockayne’s syndrome, Trichothiodystrophy
(TTD), Bloom’s syndrome (BS), Werner’s syndrome (WS), Rothmund–Thompson syndrome
(RTS), Fanconi’s anemia (FA), Nijmegen breakage sindrome (NBS), ataxia-telangiectasia-like
disease (ATLD) - are all autosomal recessive and display defects in the main damage-re‐
sponse pathways, each of which is activated by a different class of damaging agent (see for
an exhaustive review [11])
4.2. Identification of ATM substrates: Proteomic studies
It has been shown that ATM and ATR kinases mainly phosphorylate a subset of Serine and
Threonine resisdues located inside the S/T-Q motif [15]. Antibodies that allow the identifica‐
tion of proteins phosphorylated on S/T-Q residues have been generated and are commercial‐
ly available. These tools allowed therefore the development of several proteomic studies
aimed to an exhaustive identification of ATM/ATR substrates in cells treated with IR. Mat‐
suoka and colleagues performed a large-scale proteomic analysis of proteins phosphorylat‐
ed in response to DNA damage on consensus sites recognized by ATM and ATR and
identified more than 900 regulated phosphorylation sites encompassing over 700 proteins.
Functional analysis of a subset of this data set indicated that this list is highly enriched for
proteins involved in the DDR [16]. Mu and colleagues performed a similar study and identi‐
fied proteins that belong to the ubiquitin-proteasome system (UPS) to be required in mam‐
malian DNA damage checkpoint control, particularly the G1 cell cycle checkpoint, thus
revealing protein ubiquitylation as an important regulatory mechanism downstream of
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ATM/ATR activation for checkpoint control [17]. Other proteomic studies where aimed to
the analysis of the phosphoproteome dinamic changes, dependent or independent on ATM,
involved in the DNA damage response [18, 19]. Recently, a comparative analysis of ATM
deficient and proficient lymphoblastoid cells by label-free shotgun proteomic experiments
has been conducted. This study provided an insight on the functional role of ATM deficien‐
cy in cellular carbohydrate metabolism's regulation [20].
Overall proteomic approaches, identified several changes dependent on ATM expression
and activity increasing the comprehension of the DNA damage response. More intriguingly,
these studies identified as possibile substrates or effectors of ATM several proteins whose
known functions are not linked to the DDR, supporting the idea that ATM may perform
several other functions in addition of its well known role in the DDR.
5. ATM kinase: Other functions
First evidences that induce scientists to postulate a more general signaling role for ATM, in‐
dependent from DNA damage, rise from several observations made on A-T patients as well
as from a series of abnormalities of ATM-deficient cells.
First of all, cerebellar degeneration, ataxia and telangienctasia in A-T patients fit less well
with the assumption that exclusive function of ATM is in DDR. It is evident, for example,
that post-mitotic neurons of the cerebellum are less dependent on the DNA damage re‐
sponse-associated cell-cycle regulation mediated by ATM [21]. Furthermore, some A-T pa‐
tients develop insulin-resistant diabetes [22, 23]. This feature is also part of the clinical
profile of the metabolic syndrome and cannot be explained by the aberrant DNA damage
signaling activation.
Importantly, ATM-deficient cells exhibit some abnormalities, which are difficult to ascribe
only to the role of ATM in DNA damage response [12]. These alterations include:
-reduced internalization of phytohaemagglutinin (PHA), defective Ca2+ mobilization, depo‐
larization in response to extracellular K+;
• decreased duration of Ca2+ and Na+ firing;
• increased growth factor demand and defective signalling through the epidermal growth
factor (EGF) receptor;
• occurrence of markers for oxidative stress such as protein nitrosylation, increased thiol
conjugates, and lipid peroxidation.
Finally, although ATM is primarily localized to the nucleus, it has been shown that a minor
fraction of the protein is present in the cytoplasm of various cell types [24]. First evidence for
a cytoplasmic form is the discovery of ATM association with both peroxisomes and endo‐
somes [25, 26]. In neurons of the cerebellum, ATM is equally distributed between the nu‐
cleus and the cytoplasm [27, 28], which further suggests additional roles for ATM also
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outside the nucleus. ATM activation in the cytosol has been described upon insulin treat‐
ment [29] or, more recently, upon oxidative stress induction [30].
All of these observations provide evidence for additional and unexplored ATM functions
mainly linked to its extranuclear localization. However, only in the last years different
groups start to investigate more deeply and systematically the molecular mechanism and
the biological significance of these new functions. In this section a summary of these studies
will be provided.
5.1. ATM and oxidative stress
Cells living in an oxygen-rich environment are constantly challenged by oxidative stress.
Oxidative stress is defined as an imbalance between cellular oxidants and antioxidants in
which the production of Reactive Oxygen Species (ROS) exceeds the anti-oxidative capacity.
ROS include the superoxide anion radical (●O-2), hydrogen peroxide (H2O2), and the hy‐
droxyl radical (●OH). Together with other reactive nitrogen species (RNS), these ROS are the
major mediators of oxidative stress. Numerous exogenous and endogenous stress stimula‐
tors can disrupt cellular homeostasis and evoke oxidative stress. Physical factors (ultraviolet
light and ionizing radiation), oxygen level changers (hypoxia and subsequent reoxygena‐
tion) and chemical factors (hydrogen peroxide and chemotherapeutic reagents) are some of
the possible exogenous sources of ROS. Several potential endogenous sources of ROS exist
within the cell. ROS generated as byproducts and normal metabolites during aerobic metab‐
olism in mitochondria are the primary sources of ROS. In conclusion ROS produced by both
endogenous and exogenous sources either directly or indirectly activate antioxidant machi‐
nery and physiological stress signaling pathways.
Over the past two decades, evidence has accumulated that links ATM deficiency to in‐
creased oxidative stress in cells, which is thought to play a key role in neurodegeneration,
metabolic dysregulation and oncogenesis [31].
Cells from individuals affected by A-T syndrome have constitutive oxidative stress and this
altered oxidative stress has long been linked to A-T as both a cause and a consequence of the
disease [10].
Because treatment of ATM-null mice with antioxidants can ameliorate intrinsic defects in
stem cell renewal [32, 33] and delay their tumor onset [34, 35], it has been suggested that
increased accumulation of intracellular ROS associated with ATM dysfunction contributes
to the clinical features of this pathology [31, 36, 37].
Although, the increased oxidative damage associated with ATM deficiency has largely been
attributed in the past to the defects in the DDR pathway, the basis for this phenomenon re‐
mains unclear, and recent data have provided some possible new clues that are independent
of DDR. For example, a potential role for ATM in the control of an antioxidant response via
the pentose phosphate pathway (PPP) has been reported and may be relevant in ATM null
tissues showing increased oxidative stress [38]. The authors demonstrated that ATM regu‐
lates the PPP by inducing glucose-6-phosphate dehydrogenase (G6PD) activity, which in
turn promotes NADPH (Nicotinamide Adenine Dinucleotide Phosphate) production and
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nucleotide synthesis. Consistently, ATM might contribute to maintain the reducing power
of the cellular environment by promoting NADPH production. Moreover ATM can modu‐
late ROS also through modulation of mithocondria activity (see next paragraph “ATM and
Mitochondria”).
Although, it has been recognized since several years that ATM is activated also by oxidative
stress (as H2O2), the biochemical mechanisms underlying the response of ATM to oxidative
stress were described only recently. Guo and colleagues proposed that ATM functions as a
redox sensor in the cytoplasm and, as such, may regulate global cellular responses to oxida‐
tive stress [39]. ATM activation by oxidative stress involves the formation of a disulfide
bridge between cysteine (C2991) residues to form a ATM dimer [39] (described in the fol‐
lowing paragraph “Molecular mechanisms that ensure the modulation of ATM kinase activ‐
ity”). Importantly, this mode of ATM activation can occur independently of the MRN
complex, suggesting a role for ATM in signaling other than direct DNA damage.
Notably, ionizing radiations that generate DNA DSBs can also produce ROS that inactivate
key DNA repair. Hence, ATM oxidative activation may allow cells to respond to DNA DSBs
and maintain genetic integrity under these toxic conditions. ATM appears to function as a
key nodal point, bringing together DNA damage response and also the response to oxida‐
tive stress [40]. Clearly, further analysis of the importance of oxidative stress–induced acti‐
vation of ATM will illuminate the possible contribution of this feature toward specific
aspects of the A-T phenotype.
A possible role of ATM in vascular stability has long been suspected because of the manifes‐
tation of telangiectasia (dilated blood vessels) and vascular leakiness in both patients with
ataxia telangiectasia and aged ATM-deficient mice. Recently, Okuno and colleagues demon‐
strated a very interestingly correlation between oxidative stress–induced activation of ATM
and the occurrence of telangiectasia [41]. In this papers the authors demonstrated that ROS
substantially accumulates in newly formed immature vessels and activates ATM. Loss of
ATM in endothelial cells minimizes pathological ocular and tumor neoangiogenesis as a
consequence of defective oxidative defense rather than an impaired DDR [41]. This paper
provides the first evidence for a link between a clinical feature of A-T and DNA damage in‐
dependent function of ATM kinase.
5.2. ATM and mitochondria
Mitochondria play an important role in ATP synthesis and apoptosis and are also the major
source of intracellular ROS. A number of human diseases are linked to mutations of the mi‐
tochondrial genome. Among these are premature ageing, cancer, diabetes mellitus, and a
variety of syndromes involving the muscles and the central nervous system [42]. A-T is sim‐
ilar to other progressive neurological disorders that are characterized by oxidative stress
and intrinsic mitochondrial dysfunction [43].
Different studies, using immortalized cell lines established from patients with A-T, have re‐
ported that cells lacking ATM function exhibit alterations in mitochondrial homeostasis, in‐
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cluding defects in mitochondrial structure, decreased membrane potential, and respiratory
activity [44, 45].
An important step in the control of mitochondrial function is the biogenesis of these organ‐
elles, which involves mitochondrial DNA (mtDNA) replication and mitochondrial mass in‐
crease. Due to limited coding capacity of mtDNA, mitochondria rely largely on nuclear
genes (over 1000 genes) for their proliferation. Mitochondrial biogenesis therefore requires
complex coordination between the nuclear and mitochondrial genomes [46]. Upon energy
depletion, activated AMPK turns off ATP-consuming processes such as synthesis of lipids,
carbohydrates, and proteins, and turns on ATP-generating pathways including mitochon‐
drial biogenesis [47].
Interestingly ATM has been implicated in the mitochondrial biogenesis pathway mediated
through AMPK activation [48, 49] supporting a role of ATM in mitochondrial functions.
It is of interest also that several ATM substrates show mitochondrial translocation (CREB,
p53) and affect mitochondrial functions (HMGA1) [10]. Moreover A-T cells have lower cyto‐
chrome c oxidase activity than normal cells, which could explain their reduced respiratory
activity; interestingly, treatment of normal cells with an ATM inhibitor also results in re‐
duced cytochrome c oxidase activity [50]. While there are numerous external sources of
ROS, the great majority of ROS within eukaryotic cells derives from the mitochondrion as
by-products during the generation of adenosine triphosphate (ATP), through the process of
oxidative phosphorylation. These evidence lead to postulate that mitochondrial dysfunction
may be responsible for elevated ROS production and oxidative stress of A-T cells [10, 45].
However, there are some inconsistencies between these studies, such as discrepancies in the
nature of mitochondrial DNA content abnormalities. Recently Valentin-Vega and colleagues
clarify this point and report that in vivo loss of ATM results in striking mitochondrial dys‐
function in thymocytes, leading to elevated mitochondrial number and increased mitochon‐
drial ROS production. The increase in mitochondrial content is associated with defects in the
intracellular destruction of abnormal mitochondria (mitophagy). Therefore, they conclude
that ATM has major role in modulating mitochondrial function and ROS generation in vivo
and in vitro and suggest that decreased mitophagy, rather than increased mitochondrial bio‐
genesis, is associated with the increased mitochondrial content [51].
5.3. ATM, hypoxia and autophagy
Although maintenance of oxygen homeostasis is an essential cellular and systemic function,
it is only within the past few years that the molecular mechanisms underlying this funda‐
mental aspect of cell biology started to be elucidated and their connections to development,
physiology and pathophysiology have been established. HIF-1 (hypoxia-inducible factor 1)
is the transcriptional activator that functions as a master regulator of oxygen homeostasis
[52]. Recently, advances in delineating upstream signal transduction pathways leading to
the induction of HIF-1 activity, and expression of downstream target genes, have been made
and these lead to significant contribution to the understanding of oxygen homeostasis regu‐
lation [52]. Interestingly low oxygen tension or hypoxia is a common feature of all solid tu‐
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mors [53]. It is strongly associated with tumor development, malignant progression,
metastatic outgrowth, and resistance resistance to therapy and is considered an independent
prognostic indicator for poor patient prognosis in various tumor types [53].
In this context it is well established that ATM is activated under hypoxic conditions not only
in a DNA damage dependent way [54] but also through an MRN-independent mechanism
in the absence of DNA damage. Phosphorylated ATM is found in a diffuse pattern in the
nucleus [55]. The mechanism of ATM activation is not clear: although acute hypoxia induces
release of ROS from mitochondria [56], this is not essential for ATM activation under these
conditions [55]. Recently Mongiardi and colleagues have demonstrated that ATM may func‐
tion as an oxygen sensing protein. In particular they demonstrated that A-T cells exhibit a
blunted response to mild hypoxia, being defective in upregulating HIF-1α. The disability of
ATM-negative cells to upregulate HIF-1α is a consequence of an impaired sensing of oxygen
variations [57]. In addition, ATM is a direct regulator of the transcription factor complex
HIF-1, a heterodimer of HIF-1α and HIF-1β subunits that regulates metabolism, mitochon‐
drial function and angiogenesis under hypoxic conditions [58]. ATM phosphorylation of
HIF1α on Ser696 stabilizes the protein under hypoxic conditions, which promotes mTORC1
inhibition and growth suppression. Moreover authors suggest that suppression of ATM
may significantly contribute to the signalling through which TORC1 activity can remain ele‐
vated in hypoxic tumor [58].
Interestingly mTORC1 negatively regulates autophagy a catabolic process in which cells de‐
liver cytoplasmic components for degradation to the lysosome [59]. Concomitant with
mTORC1 repression by ROS, autophagy increased in cells treated with H2O2. Consistently
Alexander and colleagues demonstrated that ATM signaling in response to ROS also leads
to mTORC1 inhibition and is involved in the consequential induction of autophagy[60].
Whether autophagy is activated as a survival mechanism in response to ROS or functions in
an ATM-driven programmed cell death pathway remains to be explored.
5.4. ATM and metabolic syndrome
Metabolic syndrome is a cluster of metabolic abnormalities and related clinical syndromes
among which the most relevant ones are insulin resistance and atherosclerosis [61]. Insulin
resistance along with visceral adiposity, dyslipidemia and chronic subclinical proinflamma‐
tory state are the main characteristic features of metabolic syndrome. The role of ATM in the
regulation of metabolism is emerging as a very interesting topic. A-T patients have an in‐
creased risk of developing type 2 diabetes and display growth impairments associated with
insulin resistance and glucose intolerance [22, 23]. Diabetic complications are not considered
a primary characteristic associated with A-T owing to their late onset and the fact that most
A-T patients succumb to the disease early in life. However, several studies have demonstrat‐
ed a relationship between ATM and metabolic signaling pathways. For example, there is a
close interplay between ATM and insulin pathway (reviewed in [10]). The identification of
cytoplasmic ATM as an insulin-responsive protein provides the first indication that a defec‐
tive response to insulin could be related to the development of insulin resistance and type 2
diabetes in A–T patients [29]. Moreover ATM is required for AKT phosphorylation at Ser473
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and for translocation of the cell’s surface glucose transporter 4 (GLUT4) in response to insu‐
lin stimulation [62]. These results suggest that reduced expression of ATM may trigger the
development of insulin resistance because of the consequent downregulation of AKT activi‐
ty. Recent evidence indicates that the effects of ATM on insulin function and glucose metab‐
olism may be mediated through p53 phosphorylation [63]. Deletion of the p53- encoding
gene, or its mutation to generate p53 variants that lack the primary ATM phosphorylation
site, results in elevated ROS levels, glucose intolerance, insulin resistance, reduced AKT
phosphorylation and reduced expression of sestrin proteins, which are involved in the regu‐
lation of intracellular antioxidants [63]. These effects can be rescued by the addition of diet‐
ary antioxidants, suggesting that ATM affects insulin function and glucose metabolism by
regulating intracellular ROS levels through p53 phosphorylation. Moreover Schneider and
colleagues discovered a new relationship between ATM deficiency and metabolism in mice,
looking specifically at aspects of the metabolic syndrome such as insulin resistance, adiposi‐
ty, blood pressure, circulating cholesterol and lipid levels, and atherosclerosis. They have
shown that transplantation of bone marrow with ATM-/-ApoE-/- mice increases atherosclero‐
sis, whereas activation of ATM in ATM+/+ApoE-/- mice alleviates the vascular disease. The re‐
sults indicate that ATM deficiency causes insulin resistance, resembles the metabolic
syndrome, and increases vascular disease [64]. Interestingly, ATM has recently been identi‐
fied as a functional target of metformin, a drug widely used in the treatment of type 2 diabe‐
tes [65]. Metformin is a very interesting drug because reduces insulin resistance and
increases glucose uptake in skeletal muscle, but the mechanism of its action is not fully un‐
derstood. ATM seems to function upstream of metformin- induced AMPK activation, be‐
cause treatment of rat hepatoma cells with an ATM inhibitor reduced AMPK activation and
phosphorylation following metformin treatment [65]. However the role of ATM down‐
stream metformin treatment is very controversial and several research groups are currently
trying to clarify this point [66].
5.5. ATM and growth factors
Growth factors regulate essential processes in cells as cell proliferation, motility, survival
and morphogenesis. Several growth factors activate receptor tyrosine kinases (RTK), leading
to activation of cellular signaling pathways as PI3K/AKT signalling, which promotes cell
survival, and the mitogen-activated protein (MAP) kinase cascade [67].
First evidences of functional interactions between ATM and growth factor–mediated signal‐
ing are:
• the observation that cultured A-T cells display an increased demand for growth factors in
the media compared to wt cells;
• the identification of ability ATM as a mediator of the insulin-mediated signaling, which in
turn regulates AKT signaling [29, 62].
Moreover, it has been recently shown that also MEK/ERK signaling is modulated by ATM
[68] and that inhibition of ATM activity inhibits cell proliferation and induces apoptosis in
cancer cell lines with overactive AKT [69]. Collectively, these studies suggest that ATM may
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modulate prosurvival signaling downstream growth factor stimulation. Recently, ATM acti‐
vation has been identified also downstream the growth factor receptor HER2 in a breast can‐
cer mouse model [70]. Thus, it is clear that the ATM is activated upon growth factor
stimulation, but the mechanism of this activation is still unknown. It is tempting to speculate
that ROS production induced by growth factor stimulation could be responsible for activa‐
tion of cytoplasmic ATM. Another hypothesis is that ATM could be indirectly activated by
hyperproliferation induced by growth factor signaling.
ATM can also regulate the expression of some growth factor receptors an in particular of
some Receptor Tyrosine Kinases (RTKs). For example, the expression of the insulin-like
growth factor 1 receptor (IGF1R) is reduced in ATM-deficient cells, and the radiosensitivity
of A-T cells, following IR treatment is affected by IGF1R expression levels; both effects can
be rescued by ATM cDNA expression [71]. More recently, De Bacco and colleagues demon‐
strated that DNA damage induces ATM dependent transcription of the growth factor recep‐
tor MET and this regulation contributes to radioresistance of MET-dependent tumors [72].
Interestingly RTKs signaling is often aberrantly regulated in different type of tumors, so
overall these data suggest also a functional role for ATM in RTKs-dependent tumor progres‐
sion. In this regard, a possible role of ATM inhibition in cancer therapy will be discussed in
the paragraph “Functional links between ATM kinase and cancer”.
5.6. ATM and death receptors
The observation that A-T patients display an increased rate of lymphoma and leukaemia on‐
set, has been largely explained by the identification of ATM as a major modulator of the
DNA damage response and by the central role that physiological DNA damage plays in the
development of the immune system [73-75] (see next paragraph “Functional links between
ATM kinase and the immune system defects”).
Other important modulators of the immune system development and function are death re‐
ceptors such as Fas (CD95/APO-1) and Tumour necrosis factor (TNF)-Related Apoptosis-In‐
ducing Ligand (TRAIL). The death receptor system is essential for the regulation of the
lymphoid system homeostasis [76]. It is assumed that the negative selection process of B as
well as T cells in the germinal center (GC) and thymus, respectively, depends on Fas system
[77, 78]. Mice lacking functional Fas expression suffer from autoimmunity and increased in‐
cidence of B cell lymphomas [79, 80]. Patients with mutations that impair the function of
proteins involved in Fas-dependent apoptosis develop the autoimmune lymphoproliferative
syndrome (ALPS), which predisposes them to autoimmune disorders and to lymphoma de‐
velopment [81, 82]. Finally, Fas mutations where identified in lymphomas, in particular
those deriving from GC B cells(reviewed in [83]).
Fas (CD95/APO-1) is a transmembrane protein belonging to the tumor necrosis factor super‐
family. Upon binding of Fas ligand or agonistic antibodies, the Fas receptor recruits several
cytosolic proteins to form the death-inducing signalling complex (DISC). This is necessary to
catalyze Caspase-8 activation, which triggers the caspase cascade [84]. Caspase-8 activation
is absolutely required to trigger receptor-activated apoptotic response and its catalytic activ‐
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ity has to be tightly regulated to avoid inappropriate activation and undesired cell death.
This regulation is ensured by FLIP proteins, which are structurally similar to Procaspase-8
and can therefore compete with Procaspase-8 for binding to DISC, thus preventing Cas‐
pase-8 activation and the following apoptotic cascade [85].
Taking into account the linkage between Fas impairment and the development of immune
system tumors that are more also frequent in A-T patients, we asked whether any relation‐
ship exists between Fas and ATM signaling pathways. We could show that ATM deficiency
results in a significant resistance of lymphoid cells derived from A-T patients to Fas-induced
apoptosis. Interestingly, loss of endogenous ATM kinase activity results in the aberrant up‐
regulation of FLIP protein levels. Consistently, ATM kinase activation downregulates FLIP
protein levels providing a novel mechanism to modulate Fas sensitivity. Interestingly,
Hodgkin Lymphoma cells that are characterized by Fas-resistance and by FLIP overexpres‐
sion, may be sensitized to Fas upon ATM kinase expression, which triggers FLIP downregu‐
lation. These data point to ATM as a novel player in Fas-induced apoptosis and suggest a
novel molecular mechanism for the increased lymphoma susceptibility of A-T patients and
for the development of B cell lymphoma [86]. These observations have been further extend‐
ed also to TRAIL receptor. ATM modulates TRAIL sensitivity similarly to what described
for Fas [87]. This observation provides a rational for the employment of several DNA dam‐
aging agents largely used in chemotherapy, to enhance TRAIL sensitivity, by triggering
ATM activation which in turn drives FLIP protein downregulation [87]. This is consistent
with the identification of ATM and Chk2 activation downstream death receptor stimulation
[88]. ATM would therefore represent a crucial interplay between the modulation of DNA
damage response and death receptor induced apoptosis (reviewed in [89]).
6. Molecular mechanisms that ensure the modulation of ATM kinase
activity
ATM activation has been at first identified as a response to DSBs DNA damage. ATM is re‐
cruited to DSBs and activated by DNA damage through interactions with the MRE11–
RAD50–NBS1 (MRN) complex, which is bound to DNA ends at the site of the break. The
activated ATM is important for the initiation of DNA end resection that is an essential step
to initiate DNA repair via the homologous recombination pathway (reviewed in [11]). In vi‐
tro experiments have shown that ATM activation in response to DSBs requires the interac‐
tion with free ends DNA and with the MRN complex [90]. In this context, it has been
proposed that ATM protein exists as an inactive dimer in which the catalytic domain of one
molecule is engaged in an intermolecular interaction with the FAT domain of the other mol‐
ecule. DSBs triggers autophosphorylation on S1981, a serine residue located within the FAT
domain, and this phosphorylation causes the release of the intermolecular interaction lead‐
ing to release of an active monomer [6]. The mutation of the autophosphorylation site dis‐
rupts ATM signaling in human cells [91, 92]. Nevertheless, the functional significance of
ATM autophosphorylation is still debated as mouse models and in vitro studies have shown
that ATM autophosphorylation is not required for ATM activation by DNA damage or oxi‐
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dation [30, 90, 93, 94]. However, ATM autophosphorylation at Ser1981 is at present consid‐
ered a hallmark of ATM activation and several antibodies that specifically recognize ATM
when phosphorylated on S1981 are commercially available and commonly employed to de‐
tect the occurrence of ATM activation. Moreover, additional DSBs-induced ATM autophos‐
phorylation sites, Ser367, Ser1893 and Ser2996, have been identified and have been shown to
be required for ATM signaling in human cells [91, 92]. Global phosphoproteomic screens of
the DNA damage signalling network independently confirmed the identification of these
autophosphorylation sites. Furthermore these studies also revealed additional ATM phos‐
phorylation sites [16-19]. An updated list of ATM phosphorylation sites is avaivable at Phos‐
phoSite database http://www.phosphosite.org/proteinAction.do?id=1393&showAllSites
=true.
Several phosphatases have been identified as important modulators of ATM activity, consis‐
tently with the central role that the regulation of phosphorylation plays in the modulation of
ATM kinase activation in response to DNA damage. PP2A, PP5 and WIP1 phosphatases
regulate ATM activity [95-97]. PP2A directly modulates the state of phosphorylation of
S1981 [95]. Conversely PP5 interacts with ATM in a DNA-damage-inducible manner and its
activity sustains ATM activation [96]. Wip1 phosphatase has been identified as a novel play‐
er of the ATM-dependent signaling pathway, as it directly dephosphorylates Ser1981. Defi‐
ciency of Wip1 resulted in activation of ATM kinase, while its overexpression triggers the
downregulation of the ATM-dependent signaling cascade after DNA damage [97].
The activity of other kinases may also contribute to the modulation of ATM kinase activity.
It has been shown that Cdk5 (cyclin-dependent kinase 5), activated by DNA damage, direct‐
ly phosphorylates ATM at S794 in postmitotic neurons. This phosphorylation precedes and
is required for ATM autophosphorylation at S1981, and sustains ATM kinase activition and
signaling. The downregulation of Cdk5-ATM interplay attenuates DNA damage-induced
neuronal cell cycle reentry and expression of p53 targets PUMA and Bax, protecting neurons
from DNA damage-induced cell death [98]. Similarly, c-Abl, a non receptor tyrosine kinase
previously identified as a target and effector of ATM kinase activity in the DNA damage re‐
sponse [99, 100], has been recently identified as important modulator of ATM kinase activa‐
tion. DNA damage triggers ATM kinase dependent inducion of c-Abl activity, which in turn
triggers ATM tyrosine phosphorylation. This phosphorylation is required to enhance ATM
autophosphorylation on S1981 and ultimately to sustain ATM activity, allowing the apoptot‐
ic response [101].
It has also been shown that DNA damage induces the rapid acetylation of ATM. This acety‐
lation depends on the Tip60 histone acetyltransferase (HAT). Suppression of Tip60 blocks
ATM kinase activation and prevents the ATM-dependent phosphorylation of p53 and Chk2.
[7]. The systematic mutagenesis of lysine residues identified a single acetylation site at
K3016, which is located in the highly conserved C-terminal FATC domain [102]. K3016 ace‐
tylation is required for the DNA damage induced autophosphorylation on S1981. The acety‐
lation of ATM on lysine 3016 by Tip60 is therefore a key step linking the detection of DNA
damage and the activation of ATM kinase activity.
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Recent studies have identified a completely different mechanism for ATM activation in re‐
sponse to oxidative stress. According to the proposed models ATM would be present as in‐
active monomers (reviewed in [10]). Oxidation triggers the assembly of an active dimer in
which the two monomers are covalently linked by intermolecular disulfide bonds [30, 39].
C2991, located in the C-terminal FATC domain, has been identified as a crucial residue for
ATM activation by oxidation, as a C2991L mutant cannot be activated by H2O2. The inter‐
play between the molecular mechanisms that trigger ATM activation in response either to
DSBs or to oxidative stress has not been clearly investigated yet. It has been shown that the
S1981A mutant is still competent for activation in response to oxidation. Similarly, the
C2991L mutant is competent for DNA damage induction. ATM activation in response to
these two different stresses triggers the ATM-dependent phosphorylation of an overlapping
subset of substrates although significative differences have also been identified. As an exam‐
ple, although low levels of H2O2, which specifically trigger oxidative stress, drive the phos‐
phorylation of p53 and Chk2 proteins, similarly to what observed in response to DNA
damage, they fail to mediate histone H2AX and KAP1 phosphorylation which seem to be
peculiar for the DSBs response [30]. Importantly, the distinction between ATM activation
mediated through oxidation and that mediated by DNA damage is difficult, because oxida‐
tive stress and ROS production may usually induce DNA damage, and indeed ATM is often
exposed to both these stresses simultaneously. IR treatment is able to trigger both DNA
damage and oxidative stress suggesting that the large number of substrates identified by
proteomic approaches aimed to characterize the global pattern of ATM substrates in this
context probably represent targets from both the DNA repair and oxidation pathways. This
observation may provide an explanation for the identification, among more that 700 sub‐
strates of ATM, of proteins clearly involved not only in the control and execution of cell cy‐
cle checkpoints and DNA rapair, but also in many other pathways such as the insulin
signaling [16].
A-T has a pleiotropic phenotype that affects multiple systems, and most likely the complex
clinical features arise from the synergistic effects of a defective DNA damage response and
oxidative stress in the absence of ATM. It is intriguing to speculate that a subset of clinical
features associated with A-T might be mainly due to defects in ROS response by ATM,
whereas other features might primarily result from the impairment of a functional DNA
damage response. Interestingly, some A-T patients present a form of ATM with a truncated
C-terminal region (R3047X), that therefore lacks C2991 ([10] and references therein). Al‐
though these patients develop ataxia similarly to the others, their cells are less sensitive to IR
compared to other A-T cells. Moreover, one patient that expresses the R3047X variant does
not display immunodeficiency ([10] and references therein). Future studies will clarify
whether the variability of the clinical features displayed by A-T patients may arise from dif‐
ferent mutations which impact differently on the different functions performed by ATM.
At present the occurrence of other post-translational modification that may modulate ATM
activation by oxidative stress has not been investigated. Future systematic proteomic experi‐
ments will also define the complete profile of the oxidative stress dependent ATM sub‐
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strates. These studies will clarify the differences and the similarities among the different
mechanisms of activation of ATM kinase and their potential cross-regulation.
7. Functional links between ATM kinase and cancer
7.1. ATM expression and cancer
ATM is considered one of the principle guardians of the genome as a consequence of its
principle role in the coordination and execution of the DNA damage response. According to
this function, ATM is generally defined as a tumor suppressor gene. Several in vitro and in
vivo evidences support this idea. First of all ATM deficiency is clearly associated with an in‐
creased onset of tumorigenesis both in human and in mouse models. Indeed, about 20% of
A-T patients display a significantly higher incidence in the development of leukaemia and
lymphoma, according to the decreased ability of A-T cells to correctly handle the physiologi‐
cal double strand brakes occurring during the maturation of the immune system (reviewed
in [73, 75]). Consistently, Atm -/- mice develop lymphoma and leukaemia within the first
three months of life and die of malignant thymic lymphoma by 4–5 months of age [103-105].
Several reports also describe an increased rate in the development of solid tumors for the
heterozygous relatives of A-T patients compared to the whole population. In particular a
link between ATM heterozygosity and a higher predisposition to breast cancer onset has
been well established (reviewed in [106]). In 1987 it has been proposed that relatives of A-T
patients might be at increased risk of cancer and in particular breast cancer [107]. Later on,
several other epidemiologic studies support the same conclusion [108]. A large study con‐
ducted on 1160 relatives of 169 A-T patients, estimated the overall relative risk of breast can‐
cer in carriers to be 2.23 (95% CI = 1.16-4.28) compared to the general population [109].
Although this observation was of importance to A-T families, it was immediately clear that
it might have a much wider significance, as it has been estimated that about 1% of the whole
population might be carriers of an ATM gene mutation.
The frequency of ATM variants in human breast cancer has been largely investigated by
several laboratories. Unfortunately, the results of these studies were often inconclusive
mainly because of the low number of cases included in each study as well as for the techni‐
cal difficulties linked to the sequencing of ATM gene(reviewed in [75]). More recently, 76
rare sequence variants in the ATM gene have been analyzed in a case-control family study
of 2,570 cases of breast cancer and 1,448 controls. The risk estimates from this study suggest
that women carrying the pathogenic variant, ATM c.7271T > G, or truncating mutations
have a significantly increased risk of breast cancer with a penetrance similar to that confer‐
red by germline mutations in BRCA2 [110].
Consistently with the observation that loss of ATM expression or heterozygosity may en‐
hance cancer predisposition, some reports also describe loss of ATM expression in some tu‐
mor samples in the whole population. In particular ATM expression is strongly reduced or
lost in some leukaemia and lymphoma [73, 111-113]. The modulation of ATM expression
levels in breast cancer has been largely investigated. Several reports, demonstrate the occur‐
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rence of low levels of ATM expression in breast cancer. In particular, it has been proposed
that ATM may be aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-
triple-negative breast cancer [114, 115].
Several  molecular  mechanisms,  alternative  to  the  occurrence  of  genetic  mutations  that
lead to loss or reduction of ATM expression, have been identified. ATM is down-regulat‐
ed by N-Myc-regulated microRNA-421 and this may play a role in neuroblastoma [116].
Over-expression of miR-100 is  responsible for the low-expression of ATM in the human
glioma cell line M059J [117]. Furthermore, it has been shown that miR-18a is upregulated
in cell  lines as  well  as  in patients'  tissue samples of  breast  cancer.  miR-18a triggers  the
downregulation of ATM expression by directly targeting the ATM-3'-UTR and abrogated
the IR-induced cell cycle arrest [118].
Alternatively, ATM promoter methylation has been shown to epigenetically trigger ATM
expression downregulation in cancer. The ATM gene is aberrantly methylated and silenced
in locally advanced breast cancer [119] and aberrant methylation has been correlated with
low levels of ATM expression and increased radiosensitivity in colorectal cancer and glio‐
blastoma cell lines [120, 121].
7.2. ATM and the DDR as barrier to tumor development
Recent evidence from both cell culture, animal models and analysis of clinical specimens
show a correlation between oncogene activation or loss of tumor suppressor expression and
the occurrence of DNA replication stress and induction of the DNA Damage Re‐
sponse(DDR) (reviewed in [122]). The key initial observations that inspired the hypothesis
that tumorigenic insults may drive DDR activation as a sort of barrier that delays or prevent
cancer progression in vivo, were:
1. The occurrence of activated DNA damage signalling in a subset of human cancer cell
lines, especially those defective for p53 function.
2. The occurrence of activated DNA damage response, exemplified by Thr68 phosphoryla‐
tion on Chk2 protein, in clinical specimens of large subsets of human and lung carcino‐
mas [123].
These results suggested that some disease-associated event (not occurring in the adjacent
normal tissue) led to activation of the DDR. Therefore, it has been postulated that oncogenic
events may trigger DNA damage and the consequently activation of ATM-Chk2 signaling
cascade. To test whether this activation may represent a barrier to the transformation proc‐
ess two sets of experimental approaches have been conducted. The first one, was to develop
cell culture models of conditional oncogene activation, while the second was to extend the
analysis of the occurrence of the DDR to a large panel of human tumor biopsies derived
from various type of cancers at various stages, especially from premalignant and pre-inva‐
sive lesions which represent very early stages of cancer progression. Two studies jointly pro‐
vided evidence for a role of the DDR machinery as an inducible barrier against cancer in
clinical specimens from various tissues [124, 125]. The authors found that according to their
hypothesis, tumor cells in clinical specimens from various tissue (and not cells located in the
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adjacent normal tissue) show a costitutive activation of checkpoints kinases such as ATM
and Chk2, phosphorylated H2AX and p53 and foci formation by the DDR proteins such as
53BP1. Importantly, in the early pre invasive lesions, the DDR activation preceded occur‐
rence of mutations or loss of expression of DDR component, consistently with the idea that
the DDR barrier generates a sort of selective pression for these mutations that would allow
the escape from the barrier and consequently drive cancer progression. The DDR activation
was also well recapitulated in human cell culture models following oncogene expression, as
well as in xenograft models [124, 125]. One key question related to the induction of the DDR
as a barrier to tumor development is the mechanistic basis on the induction of DNA damage
in cancer. It has been postulated that oncogene expression triggers DNA replication stress,
including replication forks collapse and subsequent formation of DSBs [124-127]. Additional
events that may contribute to the induction of DDR in this context are telomere erosion and
ROS generation (reviewed in [122]). It has been shown that, the activation of DDR is re‐
quired for the oncogene-mediated induction of senescence [126, 127], a state of permanent
growth arrest refractory to physiological proliferation stimuli, that would counteract tumor
progression (reviewed in [128].
7.3. ATM kinase inhibition and cancer therapy
The central function of ATM in the DNA damage response and in the modulation of IR- sen‐
sitivity, suggested that the modulation of its activity may be exploited for cancer therapy.
For this reason a great effort is still ongoing to develop and improve ATM kinase inhibitors
and to define the conditions in which their employment could be beneficial for the cancer
therapy. A major obstacle in the development of a specific inhibitor of ATM catalytic activity
is linked to the high similarity among the kinase domains of the PI3K-like family proteins.
For a long time caffeine has been largely employed to modulate ATM/ATR kinase activity. It
has been shown that depending on its concentration caffeine may be able to equally block
ATM and ATR activities (10 μM) or, alternatively, to selectively interfere with ATM activity
(5 μM) [129, 130]. Later on, screening a small molecule compound library developed for the
phosphatidylinositol 3'-kinase-like kinase family, an ATP-competitive inhibitor, 2-morpho‐
lin-4-yl-6-thianthren-1-yl-pyran-4-one (KU-55933), that inhibits ATM with an IC50 of 13
nmol/L and a Ki of 2.2 nmol/L. KU-55933 has been identified. KU-55933 shows specificity
with respect to inhibition of other phosphatidylinositol 3'-kinase-like kinases. Inhibition of
ATM by KU-55933 resulted in the ablation of IR-dependent phosphorylation of several ATM
targets, including p53, H2AX, NBS1, and SMC1 and sensitize cells to the cytotoxic effects of
ionizing radiation and to the DNA double-strand break-inducing chemotherapeutic agents,
etoposide, doxorubicin, and camptothecin. Inhibition of ATM by KU-55933 also caused a
loss of ionizing radiation-induced cell cycle arrest. By contrast, KU-55933 did not potentiate
the cytotoxic effects of ionizing radiation on ataxia-telangiectasia cells, nor did it affect their
cell cycle profile after DNA damage [131]. More recently, it has been developed an im‐
proved analogue of KU-55933, named KU-60019, with Ki and IC50 values half of those of
KU-55933 [68]. KU-60019 is 10-fold more effective than KU-55933 at blocking radiation-in‐
duced phosphorylation of several ATM targets in human glioma cells. KU-60019 inhibits the
DNA damage response, reduces AKT phosphorylation and prosurvival signaling, inhibits
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migration and invasion, and effectively radiosensitizes human glioma cells [68]. A library of
1500 compounds was selected based on known kinase inhibitor templates and calculated
kinase pharmacophores from the Pfizer proprietary chemical file. These compounds were
screened with potential inhibitors being identified by a decreased ability of purified ATM
kinase to phosphorylate GST-p53[1–101] substrate. This screening approach identified the
compound CP466722 as a potential novel ATM inhibitor. The ATM-related kinase, ATR,
was not inhibited by CP466722 in vitro, although inhibitory activities against Abl and Src
kinases were reported [132]. CP466722 was not toxic and importantly, inhibition of cellular
ATM kinase activity was rapid and completely reversed by removing CP466722. Interesting‐
ly, clonogenic survival assays demonstrated that transient inhibition of ATM is sufficient to
sensitize cells to ionizing radiation and suggests that therapeutic radiosensitization may re‐
quire ATM inhibition for short periods of time [132]. Despite the large effort made so far to
improve the specificity and the efficacy of these type of inhibitors, these compounds still de‐
serve further investigation as none of them can be used in in vivo studies in animal models
because of their elevated toxicity. The identification of ATM as a novel player of other sig‐
nalling cascades, not related to the DNA damage response, raised also the question that its
ability to prevent tumorigenicity may be strictly dependent on the specific tumor context. In
particular several studies identified ATM activity as a promoter of AKT phosphorylation
and activity, which in turn sustains proliferation and cellular transformation [133] [62] [69].
These reports are consistent with the observation that ATM may be activated downstream
Receptor Tyrosine Kinases [29, 134], as well with the observation that AKT may be activated
in response to DNA damage [68, 135, 136]. Furthermore, ATM activition in response to IR
has been shown to promote the expression of MET receptor tyrosine kinase [72]. MET, in
turn, promotes cell invasion and protects cells from apoptosis, thus supporting radioresist‐
ance. Drugs targeting MET increase tumor cell radiosensitivity and prevent radiation-in‐
duced invasiveness. Overall, these observations suggest that in some conditions, ATM
activity may sustain tumorigenicity by modulating the levels of the receptor as well as by
sustaining AKT activation. Therefore its inhibition may be enhance cancer therapy efficacy.
However, the inhibition of ATM may be beneficial or conversely detrimental to cancer ther‐
apy, depending on the specific context [137], suggesting that extreme caution should be tak‐
en in this regard. Further investigation will clarify this issue.
8. Functional links between ATM kinase and the immune system defects
A-T patients display several immunological dysfunctions (reviewed in [75]). The central role
of ATM kinase in the control and execution of the DNA Damage Response (DDR), along
with the observation that DNA damage occurs physiologically to ensure the development
and the functionality of the immune system, strongly suggest that most of the immune de‐
fects linked to A-T may arise from defects in the DDR. The activation of the DDR is an im‐
portant component of the V(D)J recombination, a genetically programmed DNA
rearrangement process occurring during the early development of lymphocytes that results
in assembly of highly diversified antigen receptors essential to functional lymphocytes. De‐
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fects in repair proteins involved in rejoining V(D)J recombination-induced DSBs preclude
the generation of antigen receptors, profoundly compromising T- and B-cell development
and causing severe immune deficiencies. The role of ATM in V(D)J recombination has been
largely investigated. Immunoglobulin class switch recombination has been shown to be im‐
paired in Atm-deficient mice [138]. Moreover, during the V(D)J recombination ATM partici‐
pates to the stabilization of DNA double-strande-break complexes [139]. ATM may also
function directly in end joining, end processing or end protection [140]. A recent study re‐
ported also the persistence of chromosomal breaks in actively dividing ATM-deficient pe‐
ripheral lymphocytes [141] suggesting a role for ATM in cell-cycle control in addition to
facilitating DNA repair. However, the mechanism behind the involvement of ATM in the
cell-cycle checkpoint during V(D)J recombination, along with the functions of ATM down‐
stream targets responsible for cell-cycle control, has yet to be determined.
AT patients exhibit a wide range of cellular and humoral immune system abnormalities, re‐
sulting in variable lymphopenia [142] The most common abnormalities are the absence or
marked reduction of IgA, IgG subclasses and IgE [75, 142]. Moreover, the peripheral T-cell
population of both AT patients and Atm–/– mice is characterized by a bias toward terminal‐
ly differentiated effector cells, reflected by an extremely low ratio of naıve to memory T cells
(reviewed in [75]).
As a consequence immunodeficiency is very frequent in A-T and A-T patients display a high
predisposition to sinopulmonary infections and bacterial pneumonia and chronic lung dis‐
ease are a major cause of mortality in these patients. (reviewed in [75]).
Another important abnormality of the immune system linked to A-T pathology is the higher
incidence of leukaemia and lymphoma development observed both in mice and in humans
deficient for ATM gene expression. The risk of developing a lymphoid neoplasm is in‐
creased approximately 200-fold in AT patients compared with the normal population. The
vast majority of lymphoid tumors that develop in A-T children are T-cell ALL/lymphoma
(reviewed in [75]). Consistently, Atm–/– mice generally succumb to pre-T-ALL between 3
and 6 months of age [103-105]. A-T patients display characteristic cytogenetic abnormalities
involving chromosomes 7 and 14 that result in disruption of antigen receptor loci [74]. Some
of these chromosomal translocations may lead to the juxtaposition of a TCR locus and a pro‐
to-oncogene like TCL1 or MTCP1 (chromosomes 14 and X, respectively). T cells harboring
these translocations clonally expand, accumulate additional cytogenetic abnormalities, and
eventually develop into leukemias/lymphomas. In addition, ATM is frequently inactivated
in sporadic cancers, particularly lymphoid malignancies. Loss of 11q22-23 (the location of
the human ATM gene) is often observed in leukemias/ lymphomas [73, 111].
A recent study found a surprising role for ATM in promoting the self-renewal capacity of
hematopoietic stem cells (HSCs) [108]. The mechanism for HSC depletion in the absence of
ATM appears to be increased oxidative stress, suggesting that indeed abnormalities in the
oxidative stress response may also contribute to the immune system phenotype in addition
to the DDR deficiency [32, 33].
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9. Functional links between ATM kinase, neurodegeneration and other
neurological features
The neurodegenerative phenotype of A-T is the cardinal aspect of the disease. In A-T, the
neurodegeneration is progressive and spinocerebellar in nature, and it usually becomes ap‐
parent between 6 and 18 months of age. Patients with A-T manifest hallmarks of cerebellar
dysfunction such as dyssynergia, muscle hypotonia, truncal swaying while sitting or stand‐
ing, and sudden falls [1, 21]. Atrophy of the cerebellum, particularly is a key feature of A-T
and is evident upon magnetic resonance imaging and computed tomography imaging [21].
Purkinje cell loss is a hallmark feature of A-T and Purkinje cells have less complex arboriza‐
tions and are often localized ectopically in the molecular layer of the cerebellum [143].
Although extensive effort has been made to understand how ATM deficiency could result in
neuronal degeneration, the mechanisms behind neuronal degeneration of A–T are still poor‐
ly understood. It has been speculated that defective responses of ATM to DNA damage
could be the cause of neuronal degeneration in A–T. However, Atm_/_ mice show compro‐
mised function in DNA repair but fail to develop significant neuronal degeneration or ex‐
hibit symptoms of ataxia, suggesting a lack of correlation between dysfunction in DNA
repair and neuronal degeneration of the A–T disease [103].
Importantly, a substantial amount of ATM resides in the cytoplasm in human and mouse
brain, a sub-cellular localization incongruous for a mediator of DDR [Barlow, 2000 #283;
Boehrs, 2007 #798; Li, 2012 #820]. In the cytoplasm ATM appears to be involved in the ho‐
meostasis of lysosomes [144], in the spontaneous release of synaptic vesicles and in estab‐
lishment and maintenance of long-term potentiation (LTP) [145].
In contrast with these data, Biton and colleagues showed that ATM is predominantly nucle‐
ar in human neuronal-like cells, and that the ATM-mediated response is as robust as in pro‐
liferating cells. Knockdown of ATM abolished that response [146]. Similar observations have
been obtained from studies in murine cerebellar neurons, in which ATM seems to lacalize
essentially in the nucleus and ATM activation measured by autophosphorylation and down‐
stream signaling is comparable with that in other cell lines. This is supported by genetic evi‐
dence showing that MRE11 facilitates the activation of ATM at DNA DSBs, and that patients
that are hypomorphic for mutations in MRE11 (patients with ATLD) have a neuronal phe‐
notype that is similar to that in A-T [12].
Recently, the finding that oxidation can directly activate ATM [30], strongly suggests that
the enrolment of ATM in the oxidative stress response may provide a molecular base for
some features of neurodegeneration observed in A-T patients, which cannot be explained by
the classical ATM function in the DDR. Neurons are cells particularly vulnerable to oxida‐
tive stress as shown by the fact that oxidative injury is a key feature of both acute brain
pathologies such as stroke and traumatic brain injury and neurodegenerative diseases such
as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotropic lateral
sclerosis [147]. Neurons have a high energy demand, principally to maintain ion gradients
necessary for neuronal signal transmission as well as for the synthesis, the uptake and the
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recycling of neurotransmitters. To fulfil this requirement neurons depend principally on oxi‐
dative phosphorylation, a process that necessarily generates a certain amount of ROS as a
byproduct. At the same time neurons are relatively poor in antioxidant defenses as com‐
pared, for instance, to astrocytes [147]. Indeed, loss of ATM enhances intracellular ROS lev‐
els, and their aberrant excess, may contribute to the neurodegeneration described in A-T
[148] Although mouse mutants of ATM do not recapitulate the cerebellar degeneration,
ATM deficiency has been shown to be associated with increased levels of reactive oxygen
species in Purkinje cells [27, 149]. Furthermore, an age-dependent reduction in the number
of dopaminergic neurons present in the substantia nigra and striatum has been observed in
ATM-/- mice, which was accompanied by severe gliosis [150] suggesting that ATM-deficient
mice may model some of the neurological defects observed in A-T. Persistent oxidative
stress in the ATM-deficient brain disturbs intracellular antioxidant defence systems and re‐
dox homeostasis, thereby activating downstream signaling pathways, including those in‐
volving p38 and ERK1/2 [149]. Overall these observations suggest that, in A-T, neuronal
degeneration and ataxia do not only depend from a defective DDR but are also a conse‐
quence of the inability to mount an efficient antioxidant response because of a defective
ATM signaling. In light of this information, it is not surprising that treatment with antioxi‐
dants prevents Purkinje cell loss [151] and partially corrects neurobehavioral deficits of
Atm-/- mice [152].
In conclusion, defective DNA damage response associated with ATM deficiency might be
sufficient to induce the neurological pathology associated with A-T, but the compounded
oxidative stress and DNA repair defects in A-T patients would potentially increase the rate
and severity of neurodegeneration.
9.1. ATM and neuronal stem cells
In the normal brain, the number of neuronal stem cells (NSCs) is the result of a tightly con‐
trolled balance between self-renewal, differentiation, and death [153]. This means that con‐
trol of proliferation of the neural stem cells/precursor cells plays a critical role in
determining the number of neurons, astrocytes, and oligodendrocytes in the brain. Impor‐
tantly, ATM expression is abundant in neural stem cells (NSCs), but it is gradually reduced
as the cell differentiates [152], suggesting that ATM may play an essential role in NSC sur‐
vival and function. Paul K. Wang’s laboratory reported that ATM is required to maintain
normal self-renewal and proliferation of NSCs, due to its role in controlling the redox status.
Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated
p38 MAPK signaling [149, 154].
In addition, it is increasingly apparent that stem cell proliferation and maturation require
supportive microenvironment including astrocytes. Astrocytes have well-established roles
in regulating the microenvironment in the central nervous system, including redox homeo‐
stasis. Astrocytes also support stem cell proliferation and maintenance [155-157]. Abnormal
neuronal and astrocytic development was reported in ATM knockout mice [151, 152], which
could be the result of abnormal differentiation of NSCs. Interestingly, ATM is also required
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to maintain survival and proliferation of astrocytes by controlling the redox status of these
cells [149].
Recently, Carlessi and colleagues, used a human neural stem cell line model (ihNSCs) to get
more insight into the mechanisms of neuronal degeneration in A-T. They could show that
ATM plays a central role in terminal differentiation of ihNSCs through its function in DDR
[158]. All these data support a role of ATM in the control of neuronal differentiation though
its DDR dependent functions and oxidative stress dependent functions and suggest that de‐
fective proliferation of NSC could be in part responsible of the neurodegenerative pheno‐
type in Atm-/- mice and A-T patients.
10. General conclusions, remarks and future perspectives
The loss of ATM kinase function leads to A-T, a multisystemic disorder. Contribution from
several laboratories allowed, in the recent years, to significantly improve the knowledge on
the signalling networks involving ATM kinase. The emerging picture clearly points to ATM
as a central player of several cellular functions in addition to the well-established role as
master regulator o the DDR.
Figure 1. Schematic summary of the signalling pathways in which ATM kinase activity has been described as
an important player. ATM activity is modulated by the indicated factors. The molecular mechanisms underneath its
modulation and its function deserve further elucidation, as well as the contribution of the individual loss of each func‐
tion to the development of A-T pathology.
At present there is no therapy to prevent or cure the progression of A-T. It is possible to alle‐
viate some of the symptoms linked to immunodeficiency and deficient lung function, but
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neither the cancer predisposition, nor the progressive neurodegeneration, can be prevented.
In this regard, the identification of cytoplasmic functions of ATM, and in particular its con‐
nection with glucose metabolism and with oxidative stress, provided novel hints for the
comprehension of the development of this disorder and suggest possible alternative thera‐
peutic strategies. Treatments with antioxidants and phytonutrients have been suggested as
potential treatment strategies. Additional approaches include the employment of read-
through drugs to allow the production of ATM kinase in those patients with truncating mu‐
tations, and the development of stem cell based therapies (reviewed in [2]). The large
amount of information produced by high throughput approaches such as the proteomic
studies will deserve further attention and implementation to allow a further step into the
elucidation of the networks in which ATM is implicated and of the contribution of each in‐
teractor, modulator and substrate of ATM to their functionality.
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